Name | Title | Contact Details |
---|
Outcomes4Me has developed an Artificial Intelligence (AI)-powered patient empowerment platform for shared decision-making between patients and providers. The platform harnesses regulatory-grade, real-world data and patient experiences to generate deeper insights that improve care, accelerate research and achieve better outcomes.
Valuemedics Research is a Falls Church, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stop Heart Attack Dot Com is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Athos is a venture-backed startup developing a revolutionary product for the fitness and athletic market. We are creating next generation wearable technology that gives you real insight into how your body works as you move and combining it with a beautiful user experience that will fit right into your existing routine. Our goal is to empower you to make more informed decisions while pursuing a healthy, active lifestyle.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.